Buprenorphine and Telehealth: A New Era in Opioid Use Disorder Treatment

By Danélia Botes

August 7, 2023

Buprenorphine, the most frequently prescribed medication for opioid use disorder (OUD), is used to treat an estimated 1 to 2 million individuals annually. It’s a first-line treatment for OUD, highly effective at reducing opioid use, overdose, and all-cause mortality, and improving quality of life.

However, routine urine drug screening (UDS) to test for adherence to treatment and illicit substance use is inconsistent, despite its commonality in addiction treatment settings. There is a lack of consensus about testing schedules and how to respond to results, leading to great variation and inconsistencies.

The COVID-19 pandemic has catalysed federal policy changes, allowing for expanded telehealth-based opioid treatment (TBOT). Studies have found that TBOT may be associated with improved patient outcomes relative to in-person treatment. However, there’s an urgent need for rigorous studies exploring UDS in remote care settings.

A recent study found that most patients completed a UDS in the first 30 days of care, and an overwhelming majority within the first 90 days of care, suggesting that drug testing is feasible over a telehealth treatment platform.

Findings suggest that buprenorphine delivered in TBOT settings is an effective treatment for OUD, with low rates of opioid use across all time points in care.

However, the digital divide could exacerbate existing disparities related to health care access. It’s crucial for TBOT platforms to consider the complex interplay between clinical suitability for remote care and socioeconomic and digital barriers.

This is the first study characterising UDS administration and results in an exclusively TBOT setting, a significant step towards identifying the optimal processes for UDS in remote care settings.

Reference url

Recent Posts

South African National Health Insurance Bill

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here


The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.